Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury; a case report
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis presenting with severe acute kidney injury (AKI), consistent with rapidly progressive glomerulonephritis portends significant renal morbidity with up to 20%-25% of patients reaching end stage renal disease within a few years after dia...
Saved in:
Main Authors: | Macaulay Onuigbo (Author), Julius Seok (Author), Ikenna Anyamene (Author), Fortunate Ejimone (Author), Chinenye Eze-Raphael (Author), In-Ah Vanessa Park (Author) |
---|---|
Format: | Book |
Published: |
Society of Diabetic Nephropathy Prevention,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020) -
Epidemiology of ANCA associated vasculitis
by: Wenche Koldingsnes, et al.
Published: (2008) -
Pituitary dysfunction in patients with ANCA associated vasculitis: prevalence, presentation, and outcomes
by: Chunjia Li, et al.
Published: (2020) -
Vasculitis ANCA y esclerosis sistémica
by: Maite Hurtado, et al.
Published: (2016) -
ANCA-associated vasculitis in childhood: recent advances
by: Marta Calatroni, et al.
Published: (2017)